Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Gottfried E. Konecny, M.D.
Gottfried E. Konecny, M.D.

Specialty:

Gynecologic Oncology
Breast Medical Oncology

General Information:

Gender:
Male
Language(s):
English, German

Affiliation(s):

Associate Professor, Department of Medicine, Hematology/Oncology
Member, JCCC Signal Transduction and Therapeutics Program Area

Hospital Affiliation(s):

Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Education:

Fellowship:
Gynecologic Oncology, Mayo Clinic, 2005 - 2007
Residency:
Obstetrics and Gynecology, Klinikum Grosshadern (University of Munich), 1991 - 1996
Internship:
Obstetrics and Gynecology, Klinikum Grosshadern (University of Munich), 1989 - 1991
Medical Degree:
M.D., Ludwig-Maximilians Universitat Muenchen, 1991
Degree:
Habilitation, Ludwig-Maximilians Universitat Muenchen, 2002

Certification(s):

Medical Board Certification(s):
Obstetrics and Gynecology (Germany), 1996

Contact Information:

Phone:
(310) 586-2652
Email:

Practice Information:

Clinical Interest(s):
Breast cancer
Endometrial cancer
Ovarian cancer

Scientific Interest(s):

Dr. Gottfried Konecny is interested in the development of novel targeted therapies for ovarian, endometrial and breast cancers.

Selected Cancer-Related Publications:

Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009 Jun 20;27(18):2938-45. Epub 2009 Apr 13.

Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009 Jan 13;100(1):89-95. Epub 2008 Dec 16.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006 Feb 1;66(3):1630-9.

Konecny GE, Thomssen C, Lück HJ, Untch M, Wang HJ, Kuhn W, Eidtmann H, du Bois A, Olbricht S, Steinfeld D, Möbus V, von Minckwitz G, Dandekar S, Ramos L, Pauletti G, Pegram MD, Jänicke F, Slamon DJ. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst. 2004 Aug 4;96(15):1141-51.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.